Generated by Rank Math SEO, this is an llms.txt file designed to help LLMs better understand and index this website.

# 漢康生技股份有限公司

## Sitemaps
[XML Sitemap](https://www.hanchorbio.com/sitemap_index.xml): Includes all crawlable and indexable pages.

## 頁面
- [聯絡我們](https://www.hanchorbio.com/contact/)
- [產品管線](https://www.hanchorbio.com/pipeline/)
- [新藥研發介紹](https://www.hanchorbio.com/new-drug/)
- [隱私權條款](https://www.hanchorbio.com/privacy/)
- [核心技術](https://www.hanchorbio.com/core-technologies/)
- [加入漢康](https://www.hanchorbio.com/careers/)
- [關於漢康](https://www.hanchorbio.com/about/)
- [首頁](https://www.hanchorbio.com/)

## 利害關係人專區
- [利害關係人溝通](https://www.hanchorbio.com/stakeholders/%e5%88%a9%e5%ae%b3%e9%97%9c%e4%bf%82%e4%ba%ba%e6%ba%9d%e9%80%9a/)
- [漢康利害關係人鑑別](https://www.hanchorbio.com/stakeholders/%e6%bc%a2%e5%ba%b7%e5%88%a9%e5%ae%b3%e9%97%9c%e4%bf%82%e4%ba%ba/)

## 投資人專區
- [股東專區](https://www.hanchorbio.com/investors/shareholders/)
- [組織架構](https://www.hanchorbio.com/investors/shareholders/structure/)
- [公司治理](https://www.hanchorbio.com/investors/shareholders/governance/)
- [董事及董事會](https://www.hanchorbio.com/investors/shareholders/board/)
- [股權結構](https://www.hanchorbio.com/investors/shareholders/%e8%82%a1%e6%ac%8a%e7%b5%90%e6%a7%8b/)
- [法說會](https://www.hanchorbio.com/investors/shareholders/briefing/)
- [股東會](https://www.hanchorbio.com/investors/shareholders/meeting/)
- [功能性委員會](https://www.hanchorbio.com/investors/shareholders/%e5%8a%9f%e8%83%bd%e6%80%a7%e5%a7%94%e5%93%a1%e6%9c%83/)
- [電子書](https://www.hanchorbio.com/investors/financials/)
- [電子書](https://www.hanchorbio.com/investors/financials/reports/)
- [投資問與答](https://www.hanchorbio.com/investors/faq/)

## 最新消息
- [漢康生技推進巨噬細胞導向免疫治療策略 HCB101 全球頭頸癌研究完成首位病人給藥 HanchorBio Advances HCB101 Macrophage-Directed Immunotherapy Strategy with First Patient Dosed in Global HNSCC Study](https://www.hanchorbio.com/news/hanchorbio-advances-hcb101-macrophage-directed-immunotherapy-strategy-with-first-patient-dosed-in-global-hnscc-study/): HanchorBio announced that the first patient has been dosed in Cohort 6b of its global Phase 1b/2a HCB101-201 study
- [漢康生技取得美國 FDA Pre-IND 回覆 支持下一代三特異性免疫療法 HCB303 推進開發 HanchorBio Receives FDA Pre-IND Feedback  Supporting Advancement of HCB303, a Next-Generation Trispecific Immunotherapy](https://www.hanchorbio.com/news/hanchorbio-receives-fda-pre-ind-feedback-supporting-advancement-of-hcb303-a-next-generation-trispecific-immunotherapy/): HanchorBio announced that it has received written responses from the U.S. Food and Drug Administration (FDA) following a Type B pre-Investigational New Drug (pre-IND) submission for HCB303, the Company’s next-generation, first-in-class trispecific immunotherapy designed to simultaneously activate innate and adaptive antitumor immunity.
- [從巨噬細胞生物學到臨床開發： 漢康生技推進胃癌免疫治療的未來 From Macrophage Biology to Clinical Development:  HanchorBio Advances the Future of Gastric Cancer Immunotherapy](https://www.hanchorbio.com/news/from-macrophage-biology-to-clinical-development-hanchorbio-advances-the-future-of-gastric-cancer-immunotherapy/): HanchorBio announced insights from the “Taiwan Gastric Cancer Experts Forum on Clinical Challenges and Emerging Immunotherapy”, held August 8–9 in Taichung, Taiwan.
- [漢康-KY子公司與臺灣癌症登月計畫俞松良教授團隊建立戰略合作　共同推進精準腫瘤醫學 HanchorBio and Taiwan Cancer Moonshot Project-NTU Subteam Led by Professor Sung-Liang Yu Establish Strategic Collaboration to Advance Precision Oncology](https://www.hanchorbio.com/news/hanchorbio-and-taiwan-cancer-moonshot-project-ntu-subteam-led-by-professor-sung-liang-yu-establish-strategic-collaboration-to-advance-precision-oncology/): HanchorBio announced that its wholly owned Taiwan subsidiary has entered into a strategic collaboration with the research team led by Professor Sung-Liang Yu of National Taiwan University, a key participating team in the Taiwan Cancer Moonshot Program (TCMP). The collaboration has been formalized through a memorandum of understanding signed by HanchorBio Taiwan and Professor Yu’s team.
- [漢康生技受邀出席第九屆 BPD 生物藥工藝發展大會　分享下一代創新藥製程與 CMC 開發實務 HanchorBio Invited to Present at the 9th BPD Biopharmaceutical Process Development Conference on Next-Generation Drug Manufacturing and CMC Development](https://www.hanchorbio.com/news/hanchorbio-invited-to-present-at-the-9th-bpd-biopharmaceutical-process-development-conference-on-next-generation-drug-manufacturing-and-cmc-development/): HanchorBio announced that Vivian Kuo, PhD, Executive Director of CMC, has been invited to speak at the 2026 9th BPD Biopharmaceutical Process Development Conference.
- [漢康-KY公布主力創新藥最新臨床進展 深化巨噬細胞導向腫瘤治療策略 HanchorBio Expands Clinical Evidence Supporting Its Macrophage-Directed Oncology Strategy](https://www.hanchorbio.com/news/hanchorbio-expands-clinical-evidence-supporting-its-macrophage-directed-oncology-strategy/): HanchorBio announced updated early clinical observations from its HCB101 program.
- [漢康-KY攜「臨床定錨到平台拓展」策略亮相BIO Asia–Taiwan 2026 HanchorBio Brings Clinical Anchor-to-Platform Strategy to BIO Asia–Taiwan 2026](https://www.hanchorbio.com/news/hanchorbio-to-present-fbdb-platform-strategy-and-clinical-pipeline-progress-at-bio-asia-taiwan-2026/): HanchorBio announced that it will present its clinical development and platform strategy at BIO Asia–Taiwan 2026, taking place July 16–19, 2026, in Taipei, Taiwan.
- [漢康-KY與應世生物簽署戰略合作備忘錄，探索HCB101於難治實體瘤之聯合療法策略 HanchorBio and InxMed Sign Strategic MOU to Explore HCB101-Based Combination Therapies for Difficult-to-Treat Solid Tumors](https://www.hanchorbio.com/news/hanchorbio-and-inxmed-sign-strategic-mou-to-explore-hcb101-based-combination-therapies-for-difficult-to-treat-solid-tumors/): HanchorBio announced that its subsidiary, FBD Biologics Limited, has signed a strategic memorandum of understanding (“MOU”) with InxMed (Shanghai) Co., Ltd. (“InxMed”).
- [漢康生技宣布取得 FDA Type C 會議正式紀錄，支持 HCB101 於二線胃癌／胃食管結合部癌之明確開發路徑 HanchorBio Announces FDA Type C Meeting Minutes  Supporting a Clear Development Path for HCB101 in Second-Line Gastric/GEJ Cancer](https://www.hanchorbio.com/news/hanchorbio-announces-fda-type-c-meeting-minutes-supporting-a-clear-development-path-for-hcb101-in-second-line-gastric-gej-cancer/): HanchorBio announced receipt of the official minutes from its recent U.S. Food and Drug Administration (FDA) Type C meeting regarding the post-Phase 1 development strategy for HCB101.
- [漢康生技於 JCA-AACR 2026 發表 HCB101 胃癌及頭頸癌臨床數據，展現髓系免疫增強策略潛力 HanchorBio Showcases HCB101 Myeloid-Enhancer Strategy in Gastric Cancer and HNSCC at JCA-AACR 2026](https://www.hanchorbio.com/news/hanchorbio-showcases-hcb101-myeloid-enhancer-strategy-in-gastric-cancer-and-hnscc-at-jca-aacr-2026/): HanchorBio, Inc. announced poster presentations of HCB101 clinical data at the 9th Japanese Cancer Association (JCA) and the American Association for Cancer Research (AACR) Special Joint Conference on Novel Therapies and Diagnostics in Upper Digestive and Head and Neck Cancers, taking place June 28-30, 2026, in Kyoto, Japan.
- [漢康生技受邀於 TRPMA 生技產業交流講座分享國際化發展經驗](https://www.hanchorbio.com/news/hanchorbio-invited-to-share-international-expansion-experience-at-trpma-biotech-industry-exchange-forum/): HanchorBio Invited to Share International Expansion Experience at TRPMA Biotech Industry Exchange Forum.
- [漢康生技將出席 BIO 國際大會 2026，拓展全球合作交流機會 HanchorBio to Attend BIO International Convention 2026 to Advance Global Partnering Opportunities](https://www.hanchorbio.com/news/hanchorbio-to-attend-bio-international-convention-2026-to-advance-global-partnering-opportunities/): HanchorBio today announced that Dr. Yuehua Cong, Chief Business Officer, will attend BIO International Convention 2026
- [漢康生技於2026 ESMO靶向抗癌治療亞洲大會發表兩場口頭報告，展現下一代免疫療法臨床進展 HanchorBio Presents Two Oral Presentations at ESMO TAT Asia 2026 Highlighting Progress Across Its Next-Generation Immunotherapy Pipeline](https://www.hanchorbio.com/news/hanchorbio-presents-two-oral-presentations-at-esmo-tat-asia-2026-highlighting-progress-across-its-next-generation-immunotherapy-pipeline/): HanchorBio announced that two company-sponsored clinical programs were featured in oral presentations at the European Society for Medical Oncology Targeted Anticancer Therapies Asia Congress 2026, ESMO TAT Asia 2026, held in Hong Kong.
- [漢康生技於 FOCIS 2026 發表突破性數據，支持先天免疫產品引擎布局腫瘤與自體免疫疾病 HanchorBio Presents Late-Breaking Data at FOCIS 2026 Supporting Innate-Immune Product Engine Across Oncology and Autoimmune Disease](https://www.hanchorbio.com/news/hanchorbio-presents-late-breaking-data-at-focis-2026-supporting-innate-immune-product-engine-across-oncology-and-autoimmune-disease/): HanchorBio announced the presentation of late-breaking clinical and translational data at the Federation of Clinical Immunology Societies Annual Meeting, FOCIS 2026, being held June 9-12, 2026, in San Francisco.
- [漢康生技於 ASCO 2026 發表兩項摘要，展現 HCB101 聯合療法臨床活性與 HCB301 首次人體試驗進展 HanchorBio Presents Two ASCO 2026 Abstracts Highlighting HCB101 Combination Activity and HCB301 First-in-Human Clinical Progress](https://www.hanchorbio.com/news/hanchorbio-presents-two-asco-2026-abstracts-highlighting-hcb101-combination-activity-and-hcb301-first-in-human-clinical-progress/): HanchorBio announced updated clinical data for HCB101 and HCB301 presented at the 2026 Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago.
- [漢康-KY將於5月29日創新板掛牌　HCB101臨床進展帶動國際合作布局 HanchorBio to List on Taiwan Innovation Board at NT$120 per Share as HCB101 Clinical Data Support Global Partnering Discussions](https://www.hanchorbio.com/news/hanchorbio-to-list-on-taiwan-innovation-board-at-nt120-per-share-as-hcb101-clinical-data-support-global-partnering-discussions/): HanchorBio announced that it will be officially listed on the Taiwan Innovation Board on May 29, 2026, with an underwriting price of NT$120 per share.
- [漢康-KY引進國際策略投資人奧博資本入股 5月29日創新板掛牌 詢圈超額認購 HanchorBio Prices IPO at NT$120 Ahead of Innovation Board Listing on May 29](https://www.hanchorbio.com/news/hanchorbio-prices-ipo-at-nt120-ahead-of-innovation-board-listing-on-may-29/): HanchorBio announced the completion of bookbuilding for its initial public offering on the Taiwan Innovation Board. The offering price has been set at NT$120 per share. HanchorBio is expected to list on the Taiwan Innovation Board on May 29, 2026.
- [首筆授權金挹注營收 漢康-KY聚焦2026年臨床與商務發展重點 推進HCB101臨床開發、創新板上市進程及國際合作布局 HanchorBio Reports First Licensing Revenue and Outlines 2026 Clinical and Business Development Priorities](https://www.hanchorbio.com/news/hanchorbio-reports-first-licensing-revenue-and-outlines-2026-clinical-and-business-development-priorities/): HanchorBio today announced that its 2026 Annual General Meeting was successfully held on May 21, 2026, in Taipei, Taiwan. Shareholders approved all proposed resolutions, including the 2025 business report, financial statements, and loss offset proposal.
- [漢康生技宣布 HCB101聯合治療研究之結直腸癌臨床研究觀察到首例部分緩解（PR）HanchorBio Announces First Confirmed Partial Response in Colorectal Cancer Cohort of Ongoing HCB101-201 Combination Study](https://www.hanchorbio.com/news/hanchorbio-announces-first-confirmed-partial-response-in-colorectal-cancer-cohort-of-ongoing-hcb101-201-combination-study/): HanchorBio announced the first confirmed partial response (PR) in the colorectal cancer (CRC) cohort of its ongoing clinical study evaluating HCB101 in combination with standard-of-care regimens.
- [漢康生技HCB206拓展自體免疫疾病應用，加速推進臨床前關鍵試驗 HanchorBio Expands HCB206 Development into Autoimmune Diseases and Advances IND-Enabling Studies](https://www.hanchorbio.com/news/hanchorbio-expands-hcb206-development-into-autoimmune-diseases-and-advances-ind-enabling-studies/): HanchorBio announced that its internally developed dual-target fusion protein candidate, HCB206, has demonstrated therapeutic potential in preclinical studies across both oncology and autoimmune disease models.
- [漢康-KY上市前業績發表會 5/11登場 FBDB核心平台構築抗癌護城河 瞄準千億美元商機 HanchorBio to Hold May 11 Investor Presentation Ahead of Planned Taiwan Innovation Board Listing](https://www.hanchorbio.com/news/hanchorbio-to-hold-may-11-investor-presentation-ahead-of-planned-taiwan-innovation-board-listing/): HanchorBio announced that it will hold an investor presentation on May 11 ahead of its planned listing on the Taiwan Innovation Board later this month.
- [漢康生技與河北清華發展研究院展開 HCB101 作用機制研究合作 HanchorBio Launches HCB101 Mechanism Collaboration Study with Tsinghua University](https://www.hanchorbio.com/news/hanchorbio-launches-hcb101-mechanism-collaboration-study-with-the-institute-of-tsinghua-university/): HanchorBio started a research collaboration with the Institute of Tsinghua University, Hebei, to further characterize the antitumor mechanisms and translational biology of HCB101, the Company’s AI-guided, structurally engineered, Fc-based fusion protein targeting the CD47-SIRPα axis.
- [漢康生技於台灣癌症聯合年會 (TJCC) 展現次世代合併治療骨幹潛力、腫瘤以外平台拓展與三特異性機制進展 HanchorBio Highlights Next Generation Combination Backbone Potential, Platform Expansion Beyond Oncology, and Tri-specific Mechanistic Progress at TJCC 2026](https://www.hanchorbio.com/news/hanchorbio-highlights-next-generation-combination-backbone-potential-platform-expansion-beyond-oncology-and-tri-specific-mechanistic-progress-at-tjcc-2026/): HanchorBiopresented at the 30th Taiwan Joint Cancer Conference (TJCC 2026). Across a keynote lecture and the company symposium, HanchorBio highlighted clinical and translational data supporting HCB101 as a clinically versatile innate immune backbone and presented a working mechanism framework for its next-generation tri-specific program, HCB301.
- [漢康生技與陽明交大啟動AI賦能藥物研發合作　推進次世代創新生物藥開發 HanchorBio and NYCU Launch AI-Enabled Drug Discovery Collaboration to Advance Next-Generation Biologics](https://www.hanchorbio.com/news/hanchorbio-and-nycu-launch-ai-enabled-drug-discovery-collaboration-to-advance-next-generation-biologics/): HanchorBio started a research collaboration with the College of Engineering Bioscience at National Yang Ming Chiao Tung University (NYCU) to advance AI-enabled biologics discovery.
- [漢康生技與彭博合作 強化藥物開發及全球生物製藥戰略情報能力 HanchorBio Selects Bloomberg to Strengthen its Strategic Intelligence Across Drug Development and Global Biopharma](https://www.hanchorbio.com/news/hanchorbio-selects-bloomberg-to-strengthen-its-strategic-intelligence-across-drug-development-and-global-biopharma/): HanchorBio announced it has selected Bloomberg to support strategic decision-making across portfolio planning, pipeline development, competitive monitoring, business development, and capital markets activities.
- [漢康生技於GBCC 2026發表HCB101聯合療法一線三陰性乳癌早期數據HanchorBio Presents Early Frontline Triple-Negative Breast Cancer Data for HCB101 Combination at GBCC 2026](https://www.hanchorbio.com/news/hanchorbio-presents-early-frontline-triple-negative-breast-cancer-data-for-hcb101-combination-at-gbcc-2026/): HanchorBio announced the first dedicated presentation of HCB101 clinical data from an ongoing study evaluating HCB101 in combination with anti-PD-1 and nab-paclitaxel in patients with advanced triple-negative breast cancer (TNBC) at the Global Breast Cancer Conference 2026 (GBCC 2026) in Seoul, Korea.
- [漢康生技發布 HCB101 頭頸癌數據：單藥展現持久活性，低劑量聯合 PD-1 觀察到完全緩解 HanchorBio Reports Head and Neck Cancer Data for HCB101, Including Durable Monotherapy Activity and Complete Response at Low Dose in Combination with PD-1](https://www.hanchorbio.com/news/hanchorbio-reports-head-and-neck-cancer-data-for-hcb101-including-durable-monotherapy-activity-and-complete-response-at-low-dose-in-combination-with-pd-1/): HanchorBio reported updated clinical observations in head and neck squamous cell carcinoma (HNSCC) across both monotherapy and combination settings for HCB101, its rationally engineered SIRPα-Fc fusion protein functioning as an innate immune checkpoint blockade.
- [漢康生技報告2026年上半年科學溝通成果，並預告第二季將參與多項學術會議HanchorBio Reports Strong H1 2026 Scientific Communication Momentum and Highlights Upcoming Q2 Conference Participation](https://www.hanchorbio.com/news/hanchorbio-reports-strong-h1-2026-scientific-communication-momentum-and-highlights-upcoming-q2-conference-participation/): HanchorBio announced strong scientific communication momentum in the first half of 2026, marked by a broad series of oral, mini-oral, symposium, keynote, and poster presentations across major international scientific meetings. The Company also highlighted its upcoming and recently accepted conference participation in Q2 2026, underscoring continued external visibility across multiple programs, disease areas, and translational settings.
- [漢康生技宣布 HCB101 完成首次 2,000 公升臨床用藥 GMP 批次生產 HanchorBio Announces Successful Completion of First 2,000L GMP Clinical Batch Production of HCB101](https://www.hanchorbio.com/news/hanchorbio-announces-successful-completion-of-first-2000l-gmp-clinical-batch-production-of-hcb101/): HanchorBio's HCB101, one of its core FBDB™ (Fc-Based Designer Biologics) oncology pipeline assets, has successfully completed its first GMP clinical batch production scaled up from a 500L to a 2,000L bioreactor. This production was carried out at WuXi Biologics’ manufacturing facility, covering the full process from Drug Substance (DS) to Drug Product (DP), and achieved all predefined manufacturing objectives.
- [漢康生技受邀參加寬量國際主辦第十九屆 CEO Week 投資論壇 HanchorBio Invited to Participate in the 19th QIC CEO Week](https://www.hanchorbio.com/news/hanchorbio-invited-to-participate-in-the-19th-qic-ceo-week/): HanchorBio has been invited to participate in the 19th QIC CEO Week to meet with international institutional investors in Singapore to share corporate progress and strategic priorities.
- [漢康生技 HCB301 於台灣完成第一期臨床試驗首位患者給藥HanchorBio Doses First Patient in Taiwan in Phase 1 Trial of HCB301](https://www.hanchorbio.com/news/hanchorbio-doses-first-patient-in-taiwan-in-phase-1-trial-of-hcb301/): HanchorBio today announced that the first patient in Taiwan has been dosed in HCB301-101, the Company’s ongoing first-in-human Phase 1 clinical study of HCB301.
- [HanchorBio Signals “Backbone” Potential for HCB101  as SAB Aligns on Gastric Cancer Registrational Path隨著科學顧問委員會（SAB）就胃癌藥證註冊路徑達成共識，漢康生技釋出 HCB101 具備「治療骨幹療法」潛力的明確訊號](https://www.hanchorbio.com/news/hanchorbio-signals-backbone-potential-for-hcb101-as-sab-aligns-on-gastric-cancer-registrational-path/): HanchorBio reported outcomes from its recent Scientific Advisory Board (SAB) meeting, highlighting a shift from platform validation to asset-level positioning and registrational strategy.
- [HanchorBio Reports Early Taiwan IIT Signal in 2L CRC With Sustained Disease Control Beyond 37 Weeks漢康生技公布台灣研究者發起的臨床研究於二線大腸直腸癌之早期訊號，疾病控制可持續超過 37 週](https://www.hanchorbio.com/news/hanchorbio-reports-early-taiwan-iit-signal-in-2l-crc-with-sustained-disease-control-beyond-37-weeks/): HanchorBio today announced early findings from an ongoing investigator-initiated trial (IIT) in Taiwan evaluating HCB101-based combination therapy in patients with second-line colorectal cancer (CRC).
- [HanchorBio Reports Preliminary First-Line HER2+ Gastric Cancer Data for HCB101, Demonstrating 83.3% ORR漢康生技公布HCB101 HER2陽性胃癌一線治療初步數據 ORR達 83.3%](https://www.hanchorbio.com/news/hanchorbio-reports-preliminary-first-line-her2-gastric-cancer-data-for-hcb101-demonstrating-83-3-orr/): Hanchorbio's preliminary clinical observations from its ongoing Phase 1b/2a study evaluating HCB101-based combination therapy in first-line HER2-positive gastric cancer.
- [HanchorBio Presents at WIC-APAC 2026: The CD47 Field Enters a New Design Era漢康生技於世界免疫治療聯盟亞太區大會發表：CD47 領域邁入全新設計時代](https://www.hanchorbio.com/news/hanchorbio-to-present-at-wic-apac-2026-sharing-perspectives-on-next-generation-immunotherapy-design/): HanchorBio participated in the World Immunotherapy Council Asia-Pacific Conference (WIC-APAC 2026), to be held on March 29, 2026, at the International Convention Center, Chang Yung-Fa Foundation, Taipei, Taiwan. At the conference, Alvin Luk, PhD, MBA, CCRA, President & Chief Medical Officer (CMO) of HanchorBio (Group), and CEO of HanchorBio US, was invited to present his clinical perspectives on CD47–SIRPα in cancer immunotherapy, as well as the latest trends in next-generation multi-checkpoint engineering.
- [HanchorBio Advances Toward TWSE Innovation Board Listing to Accelerate Global Clinical Development, Platform Expansion, and International Partnering 漢康-KY獲證交所董事會通過股票創新板上市 核心技術FBDB™平台開發價值高](https://www.hanchorbio.com/news/hanchorbio-advances-toward-twse-innovation-board-listing-to-accelerate-global-clinical-development-platform-expansion-and-international-partnering/): HanchorBio, Inc., a global clinical-stage biotechnology company advancing next-generation multifunctional biologics across oncology and immune-related diseases, today announced that it has received approval from the Board of Directors of the Taiwan Stock Exchange to list on the TWSE Innovation Board, with listing anticipated in the second quarter of 2026, subject to completion of the remaining customary procedures.
- [HanchorBio Presents First Dedicated HCB101 Head and Neck Cancer Data in Oral Presentation at ICHNO 2026漢康生技於2026 ESMO頭頸癌年會首次以口頭發表 HCB101 頭頸癌臨床數據](https://www.hanchorbio.com/news/hanchorbio-presents-first-dedicated-hcb101-head-and-neck-cancer-data-in-oral-presentation-at-ichno-2026/): HanchorBio announced the first dedicated presentation of HCB101 clinical data in head and neck squamous cell carcinoma (HNSCC) in an oral presentation at ICHNO 2026 (the 10th International Congress on Innovative Approaches in Head and Neck Oncology), a joint ESTRO, EHNS, and ESMO congress, in Seville, Spain.
- [HanchorBio Expands Global Patent Protection for HCB101 with Taiwan Grant漢康生技融合蛋白創新藥HCB101獲台灣專利核准](https://www.hanchorbio.com/news/hanchorbio-expands-global-patent-protection-for-hcb101-with-taiwan-grant/): Taiwan grant adds to issued patents in the United States and Japan, further strengthening HCB101’s cross-border IP estate and supporting long-term development and partnering strategy.
- [HanchorBio Presents First Public Clinical Data for HCB301, a Tri-Specific Innate Checkpoint Molecule, at ESMO-TAT 2026漢康生技於 ESMO標靶抗癌治療大會首次公開 HCB301 人體臨床數據，展現三功能先天免疫檢查點分子的臨床開發潛力](https://www.hanchorbio.com/news/hanchorbio-presents-first-public-clinical-data-for-hcb301-a-tri-specific-innate-checkpoint-molecule-at-esmo-tat-2026/): HanchorBio, Inc. announced the presentation of first-in-human clinical data for HCB301 at the ESMO Targeted Anticancer Therapies (TAT) Congress 2026 in Paris, France.
- [HanchorBio Highlights Advancing HCB101 Clinical Program Across Monotherapy and Combination Settings at ESMO-TAT 2026漢康生技於 ESMO標靶抗癌治療大會公布 HCB101 單藥與聯合治療臨床進展，展現作為先天免疫檢查點治療骨幹的潛力](https://www.hanchorbio.com/news/hanchorbio-highlights-advancing-hcb101-clinical-program-across-monotherapy-and-combination-settings-at-esmo-tat/): HanchorBio announced the presentation of updated clinical data for HCB101 at the ESMO Targeted Anticancer Therapies (TAT) Congress 2026 in Paris, France.
- [Podcast節目上線《與漢康讀懂腫瘤免疫新藥的抗癌革命》Podcast Launch: Innovations in Immuno-Oncology](https://www.hanchorbio.com/news/podcast-decoding-the-anti-cancer-revolution-in-immuno-oncology-with-hanchorbio/): 漢康生技推出自製 Podcast 節目《與漢康讀懂腫瘤免疫新藥的抗癌革命》，從腫瘤免疫新藥的研發邏輯、商務策略到全球授權視角，帶領聽眾深入理解創新生技的關鍵趨勢與產業價值。
- [HanchorBio to Present Next-Generation Biologics Innovation at Biologics World Taiwan 2026漢康生技受邀於第13屆台灣世界生物製劑大會發表專題演講，分享次世代生物藥創新研發與CMC策略觀點](https://www.hanchorbio.com/news/hanchorbio-invited-to-speak-at-biologics-world-taiwan-2026-sharing-expert-perspectives-on-next-generation-biologics-development/): HanchorBio will participate in IMAPAC's Biologics World Taiwan 2026, taking place on March 25–26, 2026, at Hilton Taipei Sinban, Taiwan. During the event, HanchorBio’s Chairman and Chief Executive Officer, Dr. Scott Liu, and Executive Director of CMC, Dr. Vivian Kuo, will be invited as speakers. They will share insights on next-generation biologics innovation, spanning immuno-oncology, tri-specific Fc fusion protein development, and process and CMC excellence for emerging drug modalities.
- [HanchorBio Presents Dose-Dependent Tumor Responses and Deepening Tumor Shrinkage with HCB101 Triple Combination in Second-Line Gastric Cancer at the 11th Asia-Pacific Gastroesophageal Cancer Congress漢康生技於第11屆亞太胃食管癌大會發表 HCB101 三藥聯合療法於二線胃癌之具劑量依賴性的腫瘤反應與持續腫瘤縮小數據](https://www.hanchorbio.com/news/hanchorbio-presents-dose-dependent-tumor-responses-and-deepening-tumor-shrinkage-with-hcb101-triple-combination-in-second-line-gastric-cancer-at-the-11th-asia-pacific-gastroesophageal-cancer-congress/): HanchorBio, Inc. (TPEx: 7827), a global clinical-stage biotechnology company pioneering transformative immunotherapies, today presented new clinical data from its ongoing HCB101-201 Phase 1b/2a study at the 11th Asia-Pacific Gastroesophageal Cancer Congress (APGCC). The poster highlights early findings supporting dose-dependent antitumor activity of HCB101 in combination with ramucirumab and paclitaxel among patients with advanced gastric adenocarcinoma who progressed after first-line therapy.
- [HanchorBio Founder Dr. Scott Liu Invited to Moderate at BIOCHINA 2026漢康生技創辦人劉世高博士受邀出席 BIOCHINA 2026 並擔任主持人](https://www.hanchorbio.com/news/hanchorbio-founder-dr-scott-liu-invited-to-moderate-at-biochina-2026/): BIOCHINA 2026（第十一屆）易貿生物產業展覽將於 2026年3月12日至3月14日 在中國大陸蘇州舉行。漢康生技創辦人、董事長暨執行長 劉世高博士 受邀出席本屆盛會，並將擔任「抗體藥物創新開發論壇」圓桌會議主持人，同時參與專題訪談與分享，與全球產業領袖共同探討抗體藥物創新與產業合作策略。訪談主題：細分賽道聚焦——從 BD 交易看雙／多特異性抗體創新藥布局與協同合作戰略
- [HanchorBio Presents Monotherapy and Combination Clinical Data for HCB101 at AACR Immuno-Oncology 2026漢康生技於美國癌症研究協會 (AACR) 腫瘤免疫學年會發表 HCB101 單藥與聯合治療的臨床數據](https://www.hanchorbio.com/news/hanchorbio-presents-monotherapy-and-combination-clinical-data-for-hcb101-at-aacr-immuno-oncology-2026/): HanchorBio, Inc. (TPEx: 7827), a global clinical-stage biotechnology company pioneering transformative immunotherapies, today presented new clinical and translational data on HCB101, its differentiated SIRPα–Fc innate immune checkpoint fusion protein, at the American Association for Cancer Research (AACR) Immuno-Oncology Conference in Los Angeles. The presentation highlighted updated findings from the ongoing HCB101-101 Phase 1a monotherapy trial (NCT05892718) and the HCB101-201 Phase 1b/2a combination study (NCT06771622) across multiple tumor types and established oncology therapies.
- [HanchorBio Receives FDA Orphan Drug Designation for HCB101 in Gastric Cancer漢康廣譜抗癌新藥HCB101獲孤兒藥認定 推進晚期胃癌新療法](https://www.hanchorbio.com/news/hanchorbio-receives-fda-orphan-drug-designation-for-hcb101-in-gastric-cancer/): HanchorBio, Inc. (TPEx: 7827), a global clinical-stage biotechnology company advancing next-generation immunotherapies for oncology and autoimmune diseases, today announced that the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation (ODD) to HCB101 for the treatment of gastric cancer. The designation covers gastric cancer broadly, including advanced gastric adenocarcinoma in both HER2-positive and HER2-negative subtypes. This milestone underscores the significant unmet medical need in gastric cancer and provides important regulatory support for the continued clinical development of HCB101 in this patient population.
- [HanchorBio Accelerates Global Clinical Footprint with Multiple Oral and Poster Presentations in Q1 2026漢康生技全球臨床佈局加速　2026年第一季將於多場國際年會發表口頭及壁報論文](https://www.hanchorbio.com/news/hanchorbio-accelerates-global-clinical-footprint-with-multiple-oral-and-poster-presentations-in-q1-2026/): HanchorBio announced a robust schedule of scientific presentations at major international oncology congresses throughout Q1 2026. The selection of multiple abstracts, including four high-profile oral presentations, underscores the clinical maturity and global scientific recognition of HanchorBio’s proprietary pipeline.
- [HanchorBio and WuXi Biologics Enter Strategic Partnership to Advance Next-Generation Bi-and Multi-Functional Fusion Protein Pipeline漢康生技攜手藥明生物，推進新一代雙/多功能融合蛋白平臺及多專案產品線開發](https://www.hanchorbio.com/news/hanchorbio-and-wuxi-biologics-enter-strategic-partnership-to-advance-next-generation-bi-and-multi-functional-fusion-protein-pipeline/): HanchorBio, Inc. (TPEx: 7827), a global clinical-stage biotechnology company advancing next-generation immunotherapies for oncology and autoimmune diseases, and WuXi Biologics (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), jointly announced today the signing of a strategic collaboration agreement to support the development and manufacturing of multiple next-generation bi- and multi-functional fusion programs from HanchorBio’s pipeline. 致力於開發下一代免疫療法的全球臨床階段生物技術公司漢康生技與全球領先的CRDMO服務公司藥明生物共同宣佈，雙方簽署戰略合作協定，藥明生物將為漢康生技管線中多款新一代雙功能及多功能融合蛋白專案提供開發與生產服務。
- [HanchorBio Secures Japanese Patent for Engineered SIRPα-IgG4 Fusion Protein HCB101漢康生技創新 SIRPα/CD47 融合蛋白生物藥 HCB101 獲日本專利核准](https://www.hanchorbio.com/news/hcb101-japanese-patent/): Patent Approval Strengthens Global Intellectual Property Position and Supports International Licensing Strategy
- [HanchorBio Participating in the J.P. Morgan Healthcare Conference 2026漢康生技參與 2026 年 摩根大通健康醫療大會](https://www.hanchorbio.com/news/hanchorbio-participating-in-the-j-p-morgan-healthcare-conference-2026/): As the holiday season approaches, HanchorBio is kicking off 2026 with active engagement at one of the industry’s most important global healthcare events. HanchorBio is participating in the J.P. Morgan Healthcare Conference 2026, held January 12–15, 2026, in San Francisco.